查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1189754

氣道支架/肺支架市場 - 增長、趨勢、COVID-19 影響和預測 (2023-2028)

Airway Stent/Lung Stent Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 112 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計氣道/肺支架市場在預測期內的複合年增長率為 6.2%。

由於與 COVID-19 相關的呼吸窘迫增加，COVID-19 大流行對氣道/肺支架市場產生了顯著影響。 根據 2022 年 8 月發表在 PubMed 上的一篇論文，氣管支氣管支架術可以相對安全有效地治療氣管支氣管狹窄。 在全身麻醉和氣道正壓下，通常使用硬質支氣管鏡放置矽膠支架。 與本研究一樣，在靜脈體外膜氧合 (VV-ECMO) 下，通過術中支氣管支架置入術成功治療了 COVID-19 患者腫瘤引起的支氣管狹窄。 此外，2021 年 EHS 發表的一份病例報告顯示，對於 COVID-19 患者，球囊擴張聯合支架置入是替代再次手術的良好選擇。 隨著個性化患者專用氣道支架的使用和其他醫療級材料的進一步進步，氣道支架市場在未來幾年可能會出現增長。

由於肺部和呼吸系統疾病的患病率上升以及人們對微創手術的偏好增加，預計氣道/肺支架市場將呈現健康增長。 根據 Cancer Tomorrow 的報告，到 2025 年，預計肺癌患者人數將達到 2,519,283 人。 氣道和肺支架手術也是微創手術。 這意味著更短的住院時間和更少的術後疼痛。 由於微創手術的簡便性，世界各地的許多人更喜歡侵入性手術，這增加了市場價值。

根據 2022 年 4 月發表在《自然》雜誌上的一篇論文，在食管癌並發惡性氣道狹窄的患者中，預先置入氣道支架可減輕呼吸困難並需要額外的隨訪。已證明可提供治療選擇。 聯合使用經動脈灌注化療（TAIC）可以安全有效地治療食管癌並發嚴重氣道狹窄。 此外，與氣道/肺支架相關的產品批准和研發正在推動市場增長。 例如，2020 年 1 月，美國 FDA 批准了克利夫蘭診所醫生 Tom Gildea 開發的患者專用氣道支架。

因此，考慮到上述因素，氣道/肺支架市場在預測期內可能會出現增長。 然而，潛在的替代療法和與支架相關的並發症正在抑制市場增長。

氣道支架市場趨勢

預測期內矽支架有望快速增長

矽膠支架可有效維持氣道通暢，耐受性良好，幾乎沒有危及生命的並發症。 與其他材料製成的支架相比，矽膠支架安全、經濟且易於操作。 矽膠支架有球囊擴張型和擴張型。 這些支架對患有良性和癌症相關氣管支氣管狹窄的患者非常有用。 矽膠支架部分在預測期內可能會出現增長。 矽膠支架是更好的選擇，因為它們更容易移除並且不太可能損壞未來的程序。

此外，肺部和呼吸道疾病患病率的增加是市場增長的主要驅動力之一。 據 AAFA 稱，到 2021 年將有大約 2500 萬人患有哮喘病。 據同一消息來源稱，2021 年約有 500 萬美國年輕人患有哮喘病。 此外，矽膠支架可用於肺移植中的狹窄。 因此，在治療過程中它們優於其他材料。

增加矽膠支架領域的研發將提高矽膠支架的採用潛力。 根據 2021 年 4 月發表在《自然》雜誌上的一篇論文，GINA 支架的一個關鍵特徵是其靈活的動態結構，可以減小支架的橫截面積。 由於 GINA 支架有一個扁平部分，就像實際氣管支氣管樹的膜部一樣，支架更容易收縮，增強的呼氣流量有助於去除氣道分泌物。

因此，考慮到上述因素，矽膠支架部分在預測期內可能會出現增長。

預測期內北美氣道支架/肺支架市場有望增長

由於氣道肺病的高患病率、先進的醫療保健系統以及支架等醫療設備的報銷情況，北美可能會經歷氣道/肺支架市場的增長。 根據 Cancer.Net 2022 更新，到 2022 年，美國估計將有 236,740 名成年人（117,910 名男性和 118,830 名女性）被診斷出患有肺癌。 此外，根據 Asthma.ca 的 2021 年年度報告，每天都有 317 名加拿大人被新診斷出患有哮喘病。 報告稱，在加拿大，哮喘是第三大常見慢性病，影響著超過 380 萬加拿大人的生活。

此外，在整個地區開展了許多與氣道支架相關的研究活動。 例如，根據 UMMC 的 2022 年報告，定制的 3D 支架為患者提供了更輕鬆的呼吸途徑。 一名患者接受了 3D 打印矽膠支架的放置，該支架緊貼在裂隙中，裂隙將左主支氣管分為左肺的上支氣管和下支氣管，將空氣輸送到患者的肺部。 日本大量的氣道/肺支架製造公司是市場擴張的一個主要因素。 例如，2021 年 3 月，Alaxo Airway Stents（Alaxo）與加拿大阿爾伯塔省的波蒂奇學院合作，加強其在北美的影響力。

此外，政府和非政府組織不斷努力也增加了總收入。 每年 11 月，AACR 和 ALA 都會慶祝肺癌宣傳月。 通過該計劃，該組織提供了對肺癌的批判性認識，並教育公眾了解肺部健康的重要性。

因此，考慮到上述因素，北美很可能在預測期內出現增長。

氣道支架市場競爭分析

氣道支架市場是分散的，在幾個國家有各種主要參與者和本地參與者。 各大企業紛紛採取併購、戰略聯盟等戰略，以提高市場競爭力。 競爭格局包括對少數具有市場份額的知名國際和本地公司的分析。 主要競爭對手有波士頓科學公司、泰熊醫療、庫克集團、微泰（南京）、美瑞醫療等。

其他福利。

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第一章介紹

  • 研究假設和市場定義
  • 調查範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動力
    • 肺部和呼吸系統疾病患病率上升
    • 越來越喜歡微創手術
  • 市場製約因素
    • 替代療法的可用性
    • 與支架相關的並發症
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（基於價值的市場規模：百萬美元）

  • 按產品分類
    • 自擴張支架
    • 球囊擴張支架
  • 按材料
    • 金屬
      • 鎳鈦諾
      • 不銹鋼
    • 矽膠
    • 混合型
  • 按類型
    • 氣管/支氣管支架
    • 喉支架
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東和非洲
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲地區
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章競爭格局

  • 公司簡介
    • Bess medizintechnik GmbH
    • Boston Scientific Corporation
    • Cook Group
    • E. Benson Hood Laboratories Inc.
    • Efer Endoscopy
    • Endo-Flex GmbH
    • Merit Medical Systems Inc.
    • Micro-Tech（Nanjing）Co. Ltd
    • Standard Sci Tech Inc.
    • Taewoong Medical Co. Ltd

第7章 市場機會今後動向

簡介目錄
Product Code: 67340

The airway stent /lung stent market is expected to register a CAGR of 6.2% during the forecast period.

The COVID-19 pandemic had a notable impact on the airway stent /lung stent market due to the increase in respiratory difficulties associated with COVID-19. According to an article published in PubMed in August 2022, tracheobronchial stenosis can be treated relatively safely and effectively with tracheobronchial stent insertion. Under general anesthesia and positive pressure breathing, rigid bronchoscopy is commonly used to place silicone stents. As per the study, the treatment of tracheobronchial stenosis brought on by a tumor in a patient with COVID-19 was successfully managed intraoperatively by tracheobronchial stenting under venovenous extracorporeal membrane oxygenation (VV-ECMO). Furthermore, a case report published in 2021 by EHS showed that the combination of balloon dilatation and stent implantation is a good alternative to reoperation for patients with COVID-19. Due to the availability of individualized airway stents for each patient and other additional medical-grade materials advancements, the airway stent market is likely to witness growth in the coming years.

The airway stent /lung stent market is expected to witness healthy growth due to the rising prevalence of lung and respiratory disorders and people's growing preference for minimally invasive surgeries. As per the Cancer Tomorrow report, the estimated number of lung cancer cases is projected to be 2,519,283 by 2025. In addition, surgery with the airway or lung stent is minimally invasive. This means there is a lesser hospital stay and minimal pain generated post-surgery. Many people are preferring invasive surgeries around the globe due to the ease of minimally invasive surgeries, which adds value to the market.

As per the article published in April 2022 by Nature journal, the study showed that airway stents could be inserted first to reduce dyspnea intolerance in patients with esophageal cancer complicated by malignant airway stenosis and provide options for additional follow-up treatment. Sequential treatment of esophageal cancer complicated by severe airway stenosis is safe and effective when used with transarterial infusion chemotherapy (TAIC). Furthermore, product approvals and R&D relating to the airway stent/lung stent are boosting the market growth. For instance, in January 2020, the US FDA cleared patient-specific airway stents developed by Cleveland Clinic physician Tom Gildea.

Hence considering the above-mentioned factors, the airway stent /lung stent market is likely to witness growth during the forecast period. However, the availability of alternative treatments and complications associated with stents restrain the market growth.

Airway Stent Market Trends

Silicon Stents are Expected to Witness Rapid Growth During the Forecast Period

Silicon stents are effective in maintaining airway patency and are associated with good tolerance and infrequent complications that are rarely life-threatening. They are safe, cost-effective, and easy to manipulate compared to other stents with different materials. The silicon stents come in balloon-expandable and expandable versions. These stents have been very useful in patients suffering from benign and cancer-related tracheobronchial strictures. The silicon stent segment is likely to witness growth during the forecast period. Silicone stents are better options as they are simpler to remove and are less likely to damage a future procedure.

Furthermore, the increasing prevalence of lung and airway disease is one of the major driving factors for market growth. According to AAFA, approximately 25 million people had asthma in 2021. According to the same source, around 5 million American youngsters had asthma in 2021. Additionally, silicon stents are also useful in lung transplantation strictures. Thus they are preferred over other materials during the treatment.

Increased R&D in the field of silicon stents improves the chances of adoption of silicon stents. As per the article published in April 2021 by Nature journal, an important feature of the GINA stent is the flexible, dynamic structure, which enables the reduction of the stent's cross-sectional area. The GINA stent has a flat part, like the membranous portion of the actual tracheobronchial tree, which makes the stent more contractible and facilitates the removal of airway secretions through an enhanced expiratory flow.

Hence, considering the above-mentioned factors, the silicon stents segment is likely to witness growth during the forecast period.

North America is Expected to Witness a Growth in the Airway Stent/Lung Stent Market During the Forecast Period

North America is likely to experience growth in the airway stent/lung stent market due to the high prevalence of airway-lung diseases, the developed healthcare system, and the reimbursement scenario for medical devices such as stents. As per the Cancer.Net 2022 update, an estimated 236,740 adults (117,910 men and 118,830 women) in United States are likely to be diagnosed with lung cancer in 2022. Furthermore, according to the Asthma.ca 2021 annual report, every day, 317 Canadians are newly diagnosed with asthma. As per the same source, across Canada, asthma affects the lives of more than 3.8 million Canadians and is the third most common chronic disease.

In addition, many research activities are carried out relating to airway stents across the region. For instance, as per the 2022 report from the UMMC, custom-fitted 3D stent gives patients a route to easier breathing. A patient received placement of a silicone stent, made on a 3D printer, that sits snugly in the split that divides the left main bronchus to the upper and lower bronchi of the left lung that carry air to the patient's lungs. The presence of many companies that manufacture airway/lung stents in the country is a significant factor responsible for the large market size. For instance, in March 2021, Alaxo Airway Stents (Alaxo) strengthened its presence in North America by partnering with Portage College in Alberta, Canada.

Moreover, the rise in the number of initiatives undertaken by government and non-government organizations is increasing the overall revenue. Every November, the AACR and ALA celebrate Lung Cancer Awareness Month. Through the program, the organizations provide critical awareness about lung cancer and educate the public regarding the importance of lung health.

Hence considering the above-mentioned factors, North America is likely to witness growth during the forecast period.

Airway Stent Market Competitive Analysis

The market for airway stents is fragmented, with different key players and a few local companies in several countries. The major companies have adopted strategies like mergers and acquisitions and strategic alliances to gain a competitive advantage in the market. The competitive landscape includes an analysis of a few international and local companies that hold market shares and are well known. Major competitors are Boston Scientific Corporation, Taewoong Medical Co. Ltd, Cook Group, Micro-Tech (Nanjing) Co. Ltd, and Merit Medical Systems Inc., among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Lung and Rspiratory Disorders
    • 4.2.2 Growing Preference of People For Minimally Invasive Surgeries
  • 4.3 Market Restraints
    • 4.3.1 Availability of Alternative Treatments
    • 4.3.2 Complications Associated with Stents
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Product
    • 5.1.1 Self-Expandable Stents
    • 5.1.2 Balloon- Expandable Stents
  • 5.2 By Material
    • 5.2.1 Metal
      • 5.2.1.1 Nitinol
      • 5.2.1.2 Stainless Steel
    • 5.2.2 Silicone
    • 5.2.3 Hybrid
  • 5.3 By Type
    • 5.3.1 Tracheobronchial Stents
    • 5.3.2 Laryngeal Stents
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Bess medizintechnik GmbH
    • 6.1.2 Boston Scientific Corporation
    • 6.1.3 Cook Group
    • 6.1.4 E. Benson Hood Laboratories Inc.
    • 6.1.5 Efer Endoscopy
    • 6.1.6 Endo-Flex GmbH
    • 6.1.7 Merit Medical Systems Inc.
    • 6.1.8 Micro-Tech (Nanjing) Co. Ltd
    • 6.1.9 Standard Sci Tech Inc.
    • 6.1.10 Taewoong Medical Co. Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS